Zoledronic acid (Reclast)
Small molecule
Evidence outlook
Approved: Osteoporosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (3)
- Glucocorticoid-Induced Osteoporosis Reclast is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months [see Clinical Studies ( 14.4 )].
- Paget's Disease of Bone Reclast is indicated for treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see Clinical Studies ( 14.5 )].
- Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture. Treatment of Paget's disease of the bone.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00049829 NCT00049829 · Osteoporosis Registry: NCT00049829 | 3 | Incidence of hip fxs; Incidence of new vertebral fxs 2006-06 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
Other Farnesyl pyrophosphate synthase (FPPS) drugs
Zoledronic acid (Zometa), Zoledronic acid. Compare all 3 Farnesyl pyrophosphate synthase (FPPS) drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Osteoporosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zoledronic Acid (Reclast): this drug | Approved | Small molecule | Farnesyl pyrophosphate synthase (FPPS) | not yet graded | No reviewed efficacy summary in this indication | |
| Denosumab (Prolia) | Approved | Monoclonal antibody | RANKL | not yet graded | No reviewed efficacy summary in this indication | |
| Zoledronic Acid (Zometa) | Approved(overall) | Small molecule | Farnesyl pyrophosphate synthase (FPPS) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zoledronic Acid | Phase 3(overall) | Small molecule | Farnesyl pyrophosphate synthase (FPPS) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RT-102 | Discontinued | Peptide | PTH1 receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Zoledronic acid (Reclast) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.